Dynavax Technologies Corporation reaffirmed revenue guidance for the year 2023. The company is reaffirming HEPLISAV-B net product revenue guidance for full year 2023 of between $165$185 million, representing annual revenue growth of 30%-47%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.11 USD | -1.51% | +3.54% | -20.53% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.53% | 145.42Cr | |
+9.42% | 11TCr | |
+11.84% | 11TCr | |
-14.15% | 2.18TCr | |
-1.05% | 2.2TCr | |
-5.29% | 1.92TCr | |
-38.29% | 1.77TCr | |
-4.16% | 1.81TCr | |
+7.99% | 1.43TCr | |
+36.24% | 1.24TCr |
- Stock Market
- Equities
- DVAX Stock
- News Dynavax Technologies Corporation
- Dynavax Technologies Corporation Reaffirms Revenue Guidance for the Year 2023